Adipose-Derived Proinflammatory Visfatin Promotes Vascular Calcification via TLR4 and is Suppressed by Empagliflozin
A fat-derived protein drives heart calcification, but a diabetes drug blocks this pathway through a newly discovered cardioprotective mechanism.
Visfatin, elevated in patients with high coronary artery calcification scores, drives vascular calcification via TLR4-mediated VSMC osteogenic transformation; empagliflozin suppresses this pathway via NF-κB inhibition. This work identifies a novel cardioprotective mechanism of SGLT2 inhibition relevant to metabolic cardiovascular disease.
What the study was
- Study design
- Mechanistic study (animal model + in vitro + human serum)
- Population
- Murine vascular calcification model + coronary artery calcification patients
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Inflammation
Why it surfaced
Novel SGLT2i cardioprotective mechanism via visfatin/TLR4 pathway; clinically relevant to SGLT2 watchlist topic; mixed animal + human data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.